Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT07204275RecruitingPhase 2/Phase 3
Testing povetacicept for primary membranous nephropathy
This study tests an investigational drug called povetacicept for people with primary membranous nephropathy, a kidney disease. Researchers want to see if it is safe and helps reduce protein in the urine.
Montgomery, AlabamaAges 18–75 - NCT06935357RecruitingPhase 3
Felzartamab infusions for IgA nephropathy
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
Little Rock, ArkansasAges 18 years+ - NCT07582133RecruitingPhase 2
Long-term safety study of HRS-5965 for IgA kidney disease
This study follows up on patients who participated in a previous trial (HRS-5965-305) testing a drug called HRS-5965 for IgA nephropathy, a kidney disease where the immune system damages the kidneys. Researchers want to check if the drug continues to be safe and well-tolerated over a longer period.
Beijing, Beijing MunicipalityAges 18 years+ - NCT02954419Recruiting
Biomarker study in kidney disease caused by IgA
This study looks at lab markers (“biomarkers”) in people with IgA nephropathy, using kidney biopsy tissue. It may help researchers find better ways to understand the disease and tailor future care.
Guangzhou, GuangdongAges 14 years+ - NCT02986984Recruiting
Kidney biopsy study for people with diabetic kidney disease
This study aims to learn more about diabetic nephropathy (kidney problems caused by diabetes) using planned kidney tissue samples. You may benefit by helping researchers understand the disease better, and you may be eligible if you already have a medically needed kidney biopsy scheduled.
Little Rock, ArkansasAges 18–100 - NCT03929887Recruiting
Kidney biopsy patients join a kidney tissue research bank
This study builds a kidney tissue “library” to help researchers analyze kidney disease in newer ways. It may help by improving how glomerular (kidney filter) diseases are understood over time, using samples from people who already had a biopsy.
ChuncheonAges Any age - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Birmingham, AlabamaAges 18–75 - NCT04095156Recruiting
Study of immune B cells in membranous nephropathy
This study looks at immune “B cells” in people with membranous nephropathy (a kidney disease). It includes people who have received or are being considered for B-cell–depleting treatment, aiming to better understand what drives the disease and how it may respond.
Ranica, BGAges 18 years+ - NCT04326218Recruiting
Understanding Immune Causes of Kidney Membrane Disease
This study examines blood and kidney tissue samples from people with membranous nephropathy—a condition where the kidney's filtering membrane is damaged by the immune system. Researchers are trying to understand which immune markers predict how the disease will progress and respond to treatment.
Nice, Alpes MaritimeAges 18 years+ - NCT04662723RecruitingPhase 4
Personalized treatment for IgA kidney disease
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
Bari, BAAges 18 years+ - NCT04663204RecruitingPhase 2
Sparsentan study for IgA kidney disease in adults
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
Cambridge, EnglandAges 18 years+ - NCT04916132Recruiting
Diabetic kidney damage study using urine tests and biopsy
This study looks at how common diabetic kidney damage is in people with type 2 diabetes, and which factors can predict it. If you qualify, you may be asked to have a kidney biopsy to understand what’s happening inside your kidneys.
Skejby, AarhusAges 18–120 - NCT05190848Recruiting
Study of gut microbes and blood chemicals in IgA kidney disease
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
Guangzhou, GuangdongAges 16–65 - NCT05505500Recruiting
Parent and patient interviews for childhood kidney swelling
This study uses interviews to understand how swelling from nephrotic syndrome affects daily life for children and their caregivers. It may help researchers design better care by capturing the patient and parent perspective.
Ann Arbor, MichiganAges 2 years+ - NCT05696613RecruitingPhase 3
Study of a hormone gel for high-risk membranous nephropathy
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT05775042RecruitingPhase 2
CM338 for immunoglobulin A kidney disease
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
Beijing, Beijing MunicipalityAges 18–75 - NCT05888909Recruiting
Tests better diagnosis and treatment planning for kidney disease in type 2 diabetes
This trial focuses on improving how kidney damage is diagnosed and how treatment is planned for people with type 2 diabetes and kidney disease. It may help by using detailed medical history and (if done) kidney biopsy results to guide care more accurately.
BeijingAges 18 years+ - NCT06242327Recruiting
Study of outcomes in primary membranous nephropathy
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
Bergamo, BGAges 18 years+ - NCT06341205RecruitingPhase 3
Personalized rituximab for membranous nephropathy using AI
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
BesançonAges 18 years+ - NCT06350630RecruitingPhase 2
Hydroxychloroquine for IgA nephropathy
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
Clermont-FerrandAges 18 years+ - NCT06441591RecruitingPhase 2/Phase 3
Study of vinpocetine for diabetic kidney disease
This trial tests whether vinpocetine, a medicine that helps blood flow, can improve kidney function in people with type 2 diabetes and moderate to advanced kidney disease (stages 3 and 4). It may offer a new way to protect your kidneys.
Cairo, AbbasseiaAges 18 years+ - NCT06469190RecruitingEarly Phase 1
CAR NK cells for treatment-resistant kidney disease
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
ShanghaiAges 18–70 - NCT06661174Recruiting
Weight loss surgery study for diabetes with kidney problems
This study tests if bariatric surgery can help people whose diabetes is quickly damaging their kidneys. It may slow down kidney disease and improve health.
Beijing, Beijing MunicipalityAges 18–65
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 147 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.